Dianthus Therapeutics Inc (DNTH)
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for people with severe autoimmune diseases. Its pipeline includes claseprubart, a monoclonal antibody designed with an extended half-life, higher potency, and selectivity for the active C1s complement protein. The company is also advancing DNTH212, a bifunctional fusion protein that targets BDCA2 on plasmacytoid dendritic cells to lower type 1 interferon production while also inhibiting BAFF/APRIL to reduce B cell activity. Dianthus Therapeutics was founded in 2019 and is headquartered in New York, New York. Its common stock is listed on the NASDAQ under the symbol DNTH.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DNTH
|
$74.31
|
-28.7% Downside
|
Overvalued
|
$128.58
|
23.4% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-32.7x
|
4.7x
|
4,251.8x
|
5.521 B
|
4.457 B
|
0.0%
|
99.9%
|
72.8
|
—
|
75.1%
|
